2/26
06:28 am
mrk
Merck & Co., Inc. (MRK) was upgraded by Royal Bank Of Canada to "moderate buy".
Low
Report
Merck & Co., Inc. (MRK) was upgraded by Royal Bank Of Canada to "moderate buy".
2/25
05:29 pm
mrk
Merck Reshapes Leadership As HIV And RSV Prospects Take Center Stage [Yahoo! Finance]
Low
Report
Merck Reshapes Leadership As HIV And RSV Prospects Take Center Stage [Yahoo! Finance]
2/25
04:52 pm
mrk
FDA Approves NUMELVI™ (atinvicitinib tablets) for Dogs from Merck Animal Health – The First and Only Second-Generation Janus Kinase (JAK) Inhibitor for the Control of Pruritus Associated with Allergic Dermatitis [Yahoo! Finance]
Low
Report
FDA Approves NUMELVI™ (atinvicitinib tablets) for Dogs from Merck Animal Health – The First and Only Second-Generation Janus Kinase (JAK) Inhibitor for the Control of Pruritus Associated with Allergic Dermatitis [Yahoo! Finance]
2/25
04:30 pm
mrk
FDA Approves NUMELVI™ (atinvicitinib tablets) for Dogs from Merck Animal Health – The First and Only Second-Generation Janus Kinase (JAK) Inhibitor for the Control of Pruritus Associated with Allergic Dermatitis
Low
Report
FDA Approves NUMELVI™ (atinvicitinib tablets) for Dogs from Merck Animal Health – The First and Only Second-Generation Janus Kinase (JAK) Inhibitor for the Control of Pruritus Associated with Allergic Dermatitis
2/25
12:52 pm
mrk
Merck Announces Late-Breaking Data from Three Phase 3 Trials Evaluating Doravirine/Islatravir (DOR/ISL), an Investigational, Once-Daily, Two-Drug Regimen for the Treatment of Adults Living with HIV-1 at CROI 2026 [Yahoo! Finance]
Low
Report
Merck Announces Late-Breaking Data from Three Phase 3 Trials Evaluating Doravirine/Islatravir (DOR/ISL), an Investigational, Once-Daily, Two-Drug Regimen for the Treatment of Adults Living with HIV-1 at CROI 2026 [Yahoo! Finance]
2/25
12:37 pm
mrk
Merck Announces Late-Breaking Data from Three Phase 3 Trials Evaluating Doravirine/Islatravir (DOR/ISL), an Investigational, Once-Daily, Two-Drug Regimen for the Treatment of Adults Living with HIV-1 at CROI 2026
Low
Report
Merck Announces Late-Breaking Data from Three Phase 3 Trials Evaluating Doravirine/Islatravir (DOR/ISL), an Investigational, Once-Daily, Two-Drug Regimen for the Treatment of Adults Living with HIV-1 at CROI 2026
2/25
08:00 am
mrk
Merck & Co., Inc. (MRK) is now covered by Royal Bank Of Canada. They set an "outperform" rating and a $142.00 price target on the stock.
Low
Report
Merck & Co., Inc. (MRK) is now covered by Royal Bank Of Canada. They set an "outperform" rating and a $142.00 price target on the stock.
2/25
04:40 am
mrk
Merck & Co Digital Transformation Strategy Analysis Report 2025: Accelerators, Innovation Programs, Incubators, ICT, Technology Initiatives, Partnerships, Investments, Acquisitions, Network Map [Yahoo! Finance]
Low
Report
Merck & Co Digital Transformation Strategy Analysis Report 2025: Accelerators, Innovation Programs, Incubators, ICT, Technology Initiatives, Partnerships, Investments, Acquisitions, Network Map [Yahoo! Finance]
2/24
06:45 am
mrk
Merck to Participate in the TD Cowen 46th Annual Health Care Conference
Low
Report
Merck to Participate in the TD Cowen 46th Annual Health Care Conference
2/23
08:34 am
mrk
Merck reportedly ready to the splits as Keytruda patent cliff looms. Market shrugs [Yahoo! Finance]
Low
Report
Merck reportedly ready to the splits as Keytruda patent cliff looms. Market shrugs [Yahoo! Finance]
2/23
07:00 am
mrk
Merck to create separate cancer business to offset Keytruda patent loss [CNBC]
Low
Report
Merck to create separate cancer business to offset Keytruda patent loss [CNBC]
2/23
06:50 am
mrk
Merck to create separate cancer business to offset Keytruda patent loss, WSJ reports [Yahoo! Finance Canada]
Low
Report
Merck to create separate cancer business to offset Keytruda patent loss, WSJ reports [Yahoo! Finance Canada]
2/23
06:45 am
mrk
Merck Evolves Human Health Operating Structure to Support Portfolio Execution
Low
Report
Merck Evolves Human Health Operating Structure to Support Portfolio Execution
2/23
06:32 am
mrk
Merck to create separate cancer business to offset Keytruda patent loss, WSJ reports [Yahoo! Finance]
Low
Report
Merck to create separate cancer business to offset Keytruda patent loss, WSJ reports [Yahoo! Finance]
2/22
08:02 am
mrk
Merck: Why Investors Should Remain Bullish Despite Patent Risks [Seeking Alpha]
Low
Report
Merck: Why Investors Should Remain Bullish Despite Patent Risks [Seeking Alpha]
2/22
02:35 am
mrk
Deutsche Bank Upgrades Merck (MRK) to Buy, Sees “Clear Path” Beyond Keytruda Patent Cliff [Yahoo! Finance]
Low
Report
Deutsche Bank Upgrades Merck (MRK) to Buy, Sees “Clear Path” Beyond Keytruda Patent Cliff [Yahoo! Finance]
2/21
06:31 am
mrk
Merck & Co., Inc. (NYSE:MRK) was upgraded by analysts at Barclays PLC to a "strong-buy" rating.
Low
Report
Merck & Co., Inc. (NYSE:MRK) was upgraded by analysts at Barclays PLC to a "strong-buy" rating.
2/20
05:06 pm
mrk
Where is Merck & Co., Inc. (MRK) Headed According to the Street? [Yahoo! Finance]
Low
Report
Where is Merck & Co., Inc. (MRK) Headed According to the Street? [Yahoo! Finance]
2/20
09:00 am
mrk
Merck & Co., Inc. (NYSE:MRK) is now covered by analysts at Barclays PLC. They set an "overweight" rating and a $140.00 price target on the stock.
Low
Report
Merck & Co., Inc. (NYSE:MRK) is now covered by analysts at Barclays PLC. They set an "overweight" rating and a $140.00 price target on the stock.
2/19
10:02 am
mrk
?????????????????????:??????????????2026 [CNET News]
Low
Report
?????????????????????:??????????????2026 [CNET News]
2/19
05:15 am
mrk
Merck Announces Positive New Data for ENFLONSIA™ (clesrovimab) for Infants and Children Under 2 Years of Age at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease Over Two RSV Seasons
Low
Report
Merck Announces Positive New Data for ENFLONSIA™ (clesrovimab) for Infants and Children Under 2 Years of Age at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease Over Two RSV Seasons
2/18
10:38 am
mrk
Merck & Co. (MRK) Advances on Robust Keytruda Sales and Positive Clinical Trial Results [Yahoo! Finance]
Low
Report
Merck & Co. (MRK) Advances on Robust Keytruda Sales and Positive Clinical Trial Results [Yahoo! Finance]
2/18
06:45 am
mrk
Merck and Mayo Clinic Announce New Research and Development Collaboration to Support AI-Enabled Drug Discovery and Precision Medicine
Low
Report
Merck and Mayo Clinic Announce New Research and Development Collaboration to Support AI-Enabled Drug Discovery and Precision Medicine
2/17
02:27 pm
mrk
Did New KEYTRUDA Approvals Just Shift Merck's (MRK) Post-Patent Oncology Investment Narrative? [Yahoo! Finance]
Low
Report
Did New KEYTRUDA Approvals Just Shift Merck's (MRK) Post-Patent Oncology Investment Narrative? [Yahoo! Finance]
2/17
11:44 am
mrk
Health Canada Approves KEYTRUDA SC™, a subcutaneous formulation of pembrolizumab across multiple cancer indications [Globe and Mail, The (Toronto, Canada)]
Low
Report
Health Canada Approves KEYTRUDA SC™, a subcutaneous formulation of pembrolizumab across multiple cancer indications [Globe and Mail, The (Toronto, Canada)]